296277-76-4

Usage

Uses

Used in Organic Synthesis:
1-(2,4-dimethoxybenzyl)urea is used as an intermediate in organic synthesis for [application reason]. This application takes advantage of its chemical structure and reactivity to facilitate the creation of various complex molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(2,4-dimethoxybenzyl)urea is used as a pharmacological agent for [application reason]. Its potential therapeutic properties are being investigated, which may lead to the development of new drugs.
Used in Antitumor Applications:
1-(2,4-dimethoxybenzyl)urea is being investigated for its potential antitumor properties, making it a candidate for use as an anticancer agent. 1-(2,4-dimethoxybenzyl)urea may modulate various oncological signaling pathways, potentially leading to the inhibition of tumor growth and progression.
Used in Antifungal Applications:
DMBU is also being explored for its potential antifungal properties, which could make it useful as an antifungal agent in the treatment of fungal infections.
Further research is necessary to fully understand the properties and potential uses of 1-(2,4-dimethoxybenzyl)urea, as well as to optimize its applications in various industries.

Upstream product

• 20781-21-9 2,4-dimethoxybenzylamine hydrochloride 
• 57-13-6 urea 
• 590-28-3 potassium cyanate 
• 20781-20-8 2,4-Dimethoxybenzylamine 

Downstream Products

• 1187960-54-8 3-(2-cyanoacetyl)-1-[(2,4-dimethoxyphenyl)methyl]urea 
• 1224680-48-1 cyclohexylmethyl 1-(2,4-dimethyoxybenzyl)-4-(3-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 1224680-49-2 cyclohexylmethyl 1-(2,4-dimethyoxybenzyl)-4-(3-methoxyphenyl)-3,6-dimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 

Relevant academic research and scientific papers

Development of Covalent, Clickable Probes for Adenosine A1and A3Receptors

Adenosine receptors are attractive therapeutic targets for multiple conditions, including ischemia-reperfusion injury and neuropathic pain. Adenosine receptor drug discovery efforts would be facilitated by the development of appropriate tools to assist in target validation and direct receptor visualization in different native environments. We report the development of the first bifunctional (chemoreactive and clickable) ligands for the adenosine A1receptor (A1R) and adenosine A3receptor (A3R) based on an orthosteric antagonist xanthine-based scaffold and on an existing structure-activity relationship. Bifunctional ligands were functional antagonists with nanomolar affinity and irreversible binding at the A1R and A3R. In-depth pharmacological profiling of these bifunctional ligands showed moderate selectivity over A2Aand A2Badenosine receptors. Once bound to the receptor, ligands were successfully “clicked” with a cyanine-5 fluorophore containing the complementary “click” partner, enabling receptor detection. These bifunctional ligands are expected to aid in the understanding of A1R and A3R localization and trafficking in native cells and living systems.

Discovery of 3,4-dihydropyrimidin-2(1H)-ones with inhibitory activity against HIV-1 replication

3,4-Dihydropyrimidin-2(1H)-ones (DHPMs) were selected and derivatized through a HIV-1 replication assay based on GFP reporter cells. Compounds 14, 25, 31, and 36 exhibited significant inhibition of HIV-1 replication with a good safety profile. Chiral separation of each enantiomer by fractional crystallization showed that only the S enantiomer retained anti-HIV activity. Compound (S)-40, a novel and potent DHPM analog, could serve as an advanced lead for further development and the determination of the mechanism of action.

ANTI VIRAL COMPOUNDS

There is provided small molecule anti-human immunodeficiency virus (anti-HIV) compounds as well as a phenotypic cell-based high throughput screening (HTS) assay for their identification.

Synthesis of the main metabolite in human blood of the A1 adenosine receptor ligand [18F]CPFPX

In human blood, the PET radiotracer [18F]CPFPX (1) Is metabolized to numerous metabolites, one (M1) being the most prominent in plasma 30 min p.i. Because the mass of injected tracer is ≤5 nmol, concentrations In plasma are too low to analyze.